<DOC>
	<DOCNO>NCT02481453</DOCNO>
	<brief_summary>Sporadic Inclusion Body Myositis ( IBM ) frequent inflammatory myopathy patient 50 . It slowly progressive , today untreatable ( notably classical immunosuppressant ) disease . Rapamycin use organ transplantation block activity T effector cell , preserve T regulatory cell induces autophagy ( protein degradation ) , parameter impair IBM . RAPAMI prospective , randomise , control , double blind , monocentric , phase IIb trial evaluate rapamycine placebo .</brief_summary>
	<brief_title>Rapamycine v Placebo Treatment Inclusion Body Myositis</brief_title>
	<detailed_description />
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Myositis , Inclusion Body</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>IBM define Benveniste &amp; HiltonJones ( Neuromuscul Disord . 2010 ; 20 : 41421 ) Llyod criterion ( Neurology 2014 ; 83 : 426433 ) Impossiblility walk 10 meter Hypersensitivity rapamycin one compound oral solution Severe respiratory insufficiency ( FVC &lt; 50 % and/or FEV1 &lt; 50 % ) Severe chronic kidney disease ( Estimated Glomerular Filtration Rate &lt; 15 ml/min and/or proteinuria &gt; 0.3 g/24h ) Chronic liver disease ( cirrhosis and/or ALT/AST &gt; 2.5 normal value ) Cancer non remission ( necessitate specific treatment ) past 12 month Connective Tissue Disease non remission ( necessitate specific treatment ) past 12 month Pregnancy Seropositivity HIV , HCV HBV Total cholesterolemia &gt; 8 mmol/l Triglyceridemia &gt; 5 mmol/l Hemoglobinemia &lt; 11 g/dL Thrombopenia &lt; 100 000/mm3 Neutropenia &lt; 1500/ mm3 Lymphopenia &lt; 1000/ mm3</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>